Issuu on Google+

easy

safe

effective

Patented vitamin K1 supplement for horses

The missing link in bone health Make enquiry

Order now

Research and x-rays


easy

safe

effective

The missing link in bone health Product Information

Trial 1 – Bone Density

The active ingredient in BoneKare™ is Quinaquanone® a patented water soluble, bio-available form of Vitamin K1.

Marked increase in bone density in 2 year olds Trial 1 shows marked increases in bone density in two year old racehorses who were treated with Quinaquanone®

Vitamin K1 has a critical effect on the function of Osteocalcin, the protein that binds the mineral and protein in bone together.

26 two-year old thoroughbred racehorses at commencement of training for racing were divided into two groups. One group (Quinaquanone®) received 7mg formulation each day in feed for eight months. The other group (“Control”) received an apparently identical powder containing no Vitamin K1.

Vitamin K1 is naturally available in fresh, growing green pasture but it is highly unstable, being degraded by UV light, wilting or ‘wintering off ‘. Horses that do not have constant access to high quality pasture are likely to be deficient in Vitamin K1, leading to reduced bone density and bone strength.

There is an established correlation between bone density and the incidence of • OCD’s In Yearlings • DOD’s In Yearlings • DMD (Shinsoreness) in 2-Year Olds. • Horses removed from Vitamin K rich pasture and brought into a box/yard regime have demonstrated a reduction in bone density within 7-10 days. • BoneKare™ is the only European equine product to provide a stable, water soluble, bio-available form of Vitamin K1.

Digital radiographs of the left third metacarpal bone and an adjacent aluminium step wedge were taken at various intervals. The radiographic density of the bone and the stepwedge were measured and RBAE (radiographic bone aluminium equivalence) calculated. At each subsequent measurement the RBAE for each horse was compared to its initial RBAE and the percentage change recorded and is represented in the following graph: Percentage change in radiographic bone density 6 month trial in 26 two year olds in training 10 9 8 7 6 5 4 3 2 1 0 Sept 08 Oct 08

Nov 08 Dec 08

Quinaquanone Control

Make enquiry

Order now

Research and x-rays

Jan 09

Feb 09 Mar 09

Apr09

May09


easy

safe

effective

Range

Trial 2 – OCD Lesions

Significant reversal of severity of lesion score Trial 2 shows radiographs before and after supplementation with Quinaquanone®

Make enquiry

Order now

In this trial, 8 yearlings with severe OCD lesions on x-ray, were supplemented with 14mg Vitamin K1 (Quinaquanone®) per day for 3 – 7 months and then re-examined. The table shows that Vitamin K1 supplementation was associated with a significant reversal in the severity of lesion score

Research and x-rays

1

no significant visible lesions

4

likely to be career threatening

Case No.

Initial X-ray

Re X-ray

1

3

2

2

4

2

3

4

1

4

4

2

5

4

2

1

4

2

1

4

3

1

4

4


easy

safe

effective

When to use BoneKare™

BoneKare™ can be used to support horses at risk of bone related disorders. Weanlings to 4-Year Olds By feeding BoneKare™ there is a greater certainty that the horse will not develop relevant radiographic changes. This is especially important for stabled horses that don’t have constant access to green pasture. BoneKare™ may help when bone disorders already exist. During the growth phase up until approximately the 3rd to 4th year the following elements may be improved: • Increased bone density • Developmental Orthopedic Disease (DOD) includes all bone and growth cartilage abnormalities • Osteochondrosis (OCD) – bone and cartilage disease • Dorsal metacarpal disease (DMD) / Shinsoreness – disease of the 3rd Metacarpal bone • Osteoporosis • Osteoarthritis Bone Regeneration After Surgery BoneKare™ may help to rebuild the affected area after arthroscopic surgery (chip removal) or other orthopedic surgery.

Make enquiry

Order now

Research and x-rays

Older Horses Although the bone regeneration process is significantly reduced after the 3rd to 4th year of age, it may be possible through the supplementation of BoneKare™ that the progressive process of a bone disorder in an aging horse is slowed down or prevented. Manufactured in Germany by

J.A.R.A.Z. Enterprises GbR Halligenstr. 5 49661 Cloppenburg GERMANY Distributed in the UK and Ireland by

Keyflow (UK) Ltd Angel House 7 High Street Marlborough Wiltshire SN8 1AA ENGLAND Ph: +44 (0)1672 51 9000 Email: bonekare@keyflow.co Web: keyflow.co/bonekare Research: keyflow.co/bonekare-research BoneKare™ is only available from your Vet Practice.


BoneKare™ eBrochure